Friday, April 08, 2022 10:12:44 AM
So I would have Adrian, who has the most recent experience with the FDA validation process, working on the submission of our amended EUA application, as the NIH data becomes available.
But to me, perhaps even more important than an EUA authorization, is the need to produce revenue. So I would be in France, working with Cenexi and Clinigen. We have to turn our inventory into revenue, and I think that is a very doable task that does not require the NIH or the FDA. Besides, I would love to re-visit Paris.
FEATURED Fifty 1 Labs, Inc. Announces Major Strategic Advancements and Shareholder Updates • Jun 14, 2024 2:07 AM
ECGI Holdings Announces LOI to Acquire Pacific Saddlery to Capitalize on $12.72 Billion Market Potential • ECGI • Jun 13, 2024 9:50 AM
Snakes & Lattes Opens Pop-Up Location at The Wellington Market in Toronto: A New Destination for Fun and Games - Thanks 'The Well', PepsiCo, Indie Pale House & All Sponsors & Partners for Their Commitment & Assistance Throughout The Process • FUNN • Jun 13, 2024 8:18 AM
HealthLynked Introduces Innovative Online Medical Record Request Form Using DocuSign • HLYK • Jun 12, 2024 8:00 AM
Ubiquitech Software Corp (OTC:UBQU) Posts $624,585 Quarterly Revenue - Largest Quarter Since 2018 • UBQU • Jun 11, 2024 10:13 AM
Element79 Gold Corp Files for OTCQB Uplisting, Provides Financial Update • ELEM • Jun 11, 2024 9:25 AM